scispace - formally typeset
Search or ask a question
Institution

University of São Paulo

EducationSão Paulo, Brazil
About: University of São Paulo is a education organization based out in São Paulo, Brazil. It is known for research contribution in the topics: Population & Health care. The organization has 136513 authors who have published 272320 publications receiving 5127869 citations. The organization is also known as: USP & Universidade de São Paulo.


Papers
More filters
Journal ArticleDOI
28 Jan 2016-Cell
TL;DR: The complete set of genes associated with 1,122 diffuse grade II-III-IV gliomas were defined from The Cancer Genome Atlas and molecular profiles were used to improve disease classification, identify molecular correlations, and provide insights into the progression from low- to high-grade disease.

1,535 citations

Journal ArticleDOI
Nicholas J Kassebaum1, Megha Arora1, Ryan M Barber1, Zulfiqar A Bhutta2  +679 moreInstitutions (268)
TL;DR: In this paper, the authors used the Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) for all-cause mortality, cause-specific mortality, and non-fatal disease burden to derive HALE and DALYs by sex for 195 countries and territories from 1990 to 2015.

1,533 citations

Journal ArticleDOI
22 Aug 2008-Cell
TL;DR: In this paper, the authors show that senescent cells accumulate in murine livers treated to produce fibrosis, a precursor pathology to cirrhosis, derived primarily from activated hepatic stellate cells, which initially proliferate in response to liver damage and produce the extracellular matrix.

1,512 citations

Journal ArticleDOI
TL;DR: Stage 0 rectal cancer disease is associated with excellent long-term results irrespective of treatment strategy and Surgical resection may not lead to improved outcome in this situation and may be associated with high rates of temporary or definitive stoma construction and unnecessary morbidity and mortality rates.
Abstract: Multimodality approach is the preferred treatment strategy for distal rectal cancer, including radical surgery, radiotherapy and chemotherapy. A significant proportion of patients managed by surgery, performed according to established oncological principles, appear to benefit from chemoradiation (CRT) therapy either pre- or postoperatively in terms of survival and recurrence rates. Preoperative CRT may be associated with less acute toxicity, greater tumor response/sensitivity, and higher rates of sphincter-saving procedures when compared with postoperative course.1,2 Furthermore, tumor downstaging may lead to complete clinical response (defined as absence of residual primary tumor clinically detectable) or complete pathologic response (defined as absence of viable tumor cells after full pathologic examination of the resected specimen, pT0N0M0). These situations may be observed in 10% to 30% of patients treated by neoadjuvant CRT and may be referred as stage 0 disease.3–8 Surgical resection of the rectum may be associated with significant morbidity and mortality, and in these patients, with significant rates of stoma construction.9 Moreover, surgical resection may not lead to increased overall and disease-free survival in these patients. For this reason, it has been our policy to carefully follow these patients with complete clinical response assessed after 8 weeks of CRT completion by clinical, endoscopic, and radiologic studies without immediate surgery. Patients considered with incomplete clinical response are referred to radical surgery. Surprisingly, up to 7% of these patients may present complete pathologic response (pT0N0M0) without tumor cells during pathologic examination, despite incomplete clinical response characterized by a residual rectal ulcer.8 To determine the benefit of surgical resection in patients with stage 0 rectal cancer treated by preoperative CRT therapy, we compared long-term results of a group of patients with incomplete clinical response followed by radical surgery versus a group of patients with complete clinical response not operated on.

1,497 citations

Journal ArticleDOI
Mohammad H. Forouzanfar1, Patrick Liu1, Gregory A. Roth1, Marie Ng1, Stan Biryukov1, Laurie B. Marczak1, Lily Alexander1, Kara Estep1, Kalkidan Hassen Abate2, Tomi Akinyemiju3, Raghib Ali4, Nelson Alvis-Guzman5, Peter Azzopardi, Amitava Banerjee6, Till Bärnighausen7, Till Bärnighausen8, Arindam Basu9, Tolesa Bekele10, Derrick A Bennett4, Sibhatu Biadgilign, Ferrán Catalá-López11, Ferrán Catalá-López12, Valery L. Feigin13, João C. Fernandes14, Florian Fischer15, Alemseged Aregay Gebru16, Philimon Gona17, Rajeev Gupta, Graeme J. Hankey18, Graeme J. Hankey19, Jost B. Jonas20, Suzanne E. Judd3, Young-Ho Khang21, Ardeshir Khosravi, Yun Jin Kim22, Ruth W Kimokoti23, Yoshihiro Kokubo, Dhaval Kolte24, Alan D. Lopez25, Paulo A. Lotufo26, Reza Malekzadeh, Yohannes Adama Melaku16, Yohannes Adama Melaku27, George A. Mensah28, Awoke Misganaw1, Ali H. Mokdad1, Andrew E. Moran29, Haseeb Nawaz30, Bruce Neal, Frida Namnyak Ngalesoni31, Takayoshi Ohkubo32, Farshad Pourmalek33, Anwar Rafay, Rajesh Kumar Rai, David Rojas-Rueda, Uchechukwu K.A. Sampson28, Itamar S. Santos26, Monika Sawhney34, Aletta E. Schutte35, Sadaf G. Sepanlou, Girma Temam Shifa36, Girma Temam Shifa37, Ivy Shiue38, Ivy Shiue39, Bemnet Amare Tedla40, Amanda G. Thrift41, Marcello Tonelli42, Thomas Truelsen43, Nikolaos Tsilimparis, Kingsley N. Ukwaja, Olalekan A. Uthman44, Tommi Vasankari, Narayanaswamy Venketasubramanian, Vasiliy Victorovich Vlassov45, Theo Vos1, Ronny Westerman, Lijing L. Yan46, Yuichiro Yano47, Naohiro Yonemoto, Maysaa El Sayed Zaki, Christopher J L Murray1 
10 Jan 2017-JAMA
TL;DR: In international surveys, although there is uncertainty in some estimates, the rate of elevatedSBP (≥110-115 and ≥140 mm Hg) increased substantially between 1990 and 2015, and DALYs and deaths associated with elevated SBP also increased.
Abstract: Importance Elevated systolic blood (SBP) pressure is a leading global health risk. Quantifying the levels of SBP is important to guide prevention policies and interventions. Objective To estimate the association between SBP of at least 110 to 115 mm Hg and SBP of 140 mm Hg or higher and the burden of different causes of death and disability by age and sex for 195 countries and territories, 1990-2015. Design A comparative risk assessment of health loss related to SBP. Estimated distribution of SBP was based on 844 studies from 154 countries (published 1980-2015) of 8.69 million participants. Spatiotemporal Gaussian process regression was used to generate estimates of mean SBP and adjusted variance for each age, sex, country, and year. Diseases with sufficient evidence for a causal relationship with high SBP (eg, ischemic heart disease, ischemic stroke, and hemorrhagic stroke) were included in the primary analysis. Main Outcomes and Measures Mean SBP level, cause-specific deaths, and health burden related to SBP (≥110-115 mm Hg and also ≥140 mm Hg) by age, sex, country, and year. Results Between 1990-2015, the rate of SBP of at least 110 to 115 mm Hg increased from 73 119 (95% uncertainty interval [UI], 67 949-78 241) to 81 373 (95% UI, 76 814-85 770) per 100 000, and SBP of 140 mm Hg or higher increased from 17 307 (95% UI, 17 117-17 492) to 20 526 (95% UI, 20 283-20 746) per 100 000. The estimated annual death rate per 100 000 associated with SBP of at least 110 to 115 mm Hg increased from 135.6 (95% UI, 122.4-148.1) to 145.2 (95% UI 130.3-159.9) and the rate for SBP of 140 mm Hg or higher increased from 97.9 (95% UI, 87.5-108.1) to 106.3 (95% UI, 94.6-118.1). Loss of disability-adjusted life-years (DALYs) associated with SBP of at least 110 to 115 mm Hg increased from 148 million (95% UI, 134-162 million) to 211 million (95% UI, 193-231 million), and for SBP of 140 mm Hg or higher, the loss increased from 95.9 million (95% UI, 87.0-104.9 million) to 143.0 million (95% UI, 130.2-157.0 million). The largest numbers of SBP-related deaths were caused by ischemic heart disease (4.9 million [95% UI, 4.0-5.7 million]; 54.5%), hemorrhagic stroke (2.0 million [95% UI, 1.6-2.3 million]; 58.3%), and ischemic stroke (1.5 million [95% UI, 1.2-1.8 million]; 50.0%). In 2015, China, India, Russia, Indonesia, and the United States accounted for more than half of the global DALYs related to SBP of at least 110 to 115 mm Hg. Conclusions and Relevance In international surveys, although there is uncertainty in some estimates, the rate of elevated SBP (≥110-115 and ≥140 mm Hg) increased substantially between 1990 and 2015, and DALYs and deaths associated with elevated SBP also increased. Projections based on this sample suggest that in 2015, an estimated 3.5 billion adults had SBP of at least 110 to 115 mm Hg and 874 million adults had SBP of 140 mm Hg or higher.

1,494 citations


Authors

Showing all 138091 results

NameH-indexPapersCitations
George M. Whitesides2401739269833
Peter Libby211932182724
Robert C. Nichol187851162994
Paul M. Thompson1832271146736
Terrie E. Moffitt182594150609
Douglas R. Green182661145944
Richard B. Lipton1762110140776
Robin M. Murray1711539116362
George P. Chrousos1691612120752
David A. Bennett1671142109844
Barry M. Popkin15775190453
David H. Adams1551613117783
Joao Seixas1531538115070
Matthias Egger152901184176
Ichiro Kawachi149121690282
Network Information
Related Institutions (5)
Federal University of Rio de Janeiro
89.1K papers, 1.5M citations

98% related

State University of Campinas
104.6K papers, 1.8M citations

97% related

Universidade Federal do Rio Grande do Sul
89.4K papers, 1.4M citations

97% related

Universidade Federal de Minas Gerais
75.6K papers, 1.2M citations

96% related

Sao Paulo State University
100.4K papers, 1.3M citations

96% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20241
2023331
20222,547
202118,134
202017,960
201916,297